Conformational Studies by Dynamic NMR. 93.1 Stereomutation, Enantioseparation, and Absolute Configuration of the Atropisomers of Diarylbicyclononanes
摘要:
The structure of 9-(4-methoxyphenyl)-9-(3-methylphenyl) bicyclo[3.3.1]nonane (1) has been determined by single-crystal X-ray diffraction, and the rotation barriers about the two aryl-C9 bonds have been measured by variable temperature NMR spectroscopy in solution. In the case of 9(4-methoxyphenyl)-9-(1-naphthyl)bicyclo[3.3.1]nonane (3), the barrier involving the naphthyl-C9 rotation was found to be so high as to allow the physical separation of the two atropisomers by enantioselective HPLC at ambient temperature: the absolute configuration could be established on the basis of the corresponding CD spectra. It was also observed that the Ar-C9 rotation barriers of monoaryl-substituted nonanes are much lower than those of the corresponding diaryl-substituted nonanes.
Disclosed herein are methods of treatment and prevention of diseases and disorders related to estrogen receptors comprising administering novel di-aromatic compounds to patients in need thereof.
[EN] COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS<br/>[FR] COMPOSES PRESENTANT UNE ACTIVITE AU NIVEAU DES RECEPTEURS D'OESTROGENES
申请人:ACADIA PHARM INC
公开号:WO2007056500A2
公开(公告)日:2007-05-18
[EN] Disclosed herein are novel di-aromatic compounds and methods for using various di- aromatic compounds for treatment and prevention of diseases and disorders related to estrogen receptors. [FR] La présente invention concerne de nouveaux composés diaromatiques et des procédés destinés à une utilisation de divers composés diaromatiques en vue de traiter et de prévenir des pathologies et des troubles liés aux récepteurs d'oetrogènes.
[EN] COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS<br/>[FR] COMPOSÉS PRÉSENTANT UNE ACTIVITÉ AUX RÉCEPTEURS D'OETROGÈNE
申请人:ACADIA PHARM INC
公开号:WO2008033894A2
公开(公告)日:2008-03-20
[EN] Disclosed herein are methods of treating neuropathic pain, reducing inflammation, reducing IL-4 levels, and reducing IFN-? levels, using various di-aromatic compounds for use as estrogen receptors ß agonists. [FR] L'invention concerne des procédés de traitement de la douleur neuropathique, de diminution des inflammations, de réduction des niveaux de IL-4 et de réduction des niveaux de IFN-? au moyen de divers composés di-aromatiques utilisés en qualité d'agonistes ß de récepteurs d'oetrogène.